U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07295509) titled 'A Study of Picankibart in Patients With Active Psoriatic Arthritis' on Nov. 24.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase II/III clinical trial evaluating the efficacy and safety of picankibart (IBI112) in patients with active psoriatic arthritis (PsA). The study consists of two stages: Phase II dose-finding (n=90) and Phase III confirmatory (n=132). Participants will receive subcutaneous (SC) injections of either picankibart (200mg) or placebo with different dosing schedules, with placebo crossover to active treatment at Week 26. The Phase II portion will identify optimal dosing for Ph...